INTRODUCTION
============

Recombinase-mediated, conditional gene inactivation ([@b1]--[@b3]) has emerged as a powerful genetic method for the determination of the complex function of genes in mammals *in vivo*. While permanent germline gene inactivation in embryonic stem (ES) cells using insertional mutagenesis techniques has been developed in commercial and academic settings to provide large-scale genome coverage ([@b4]--[@b6]), similar approaches for conditional mutagenesis are not currently available. We have developed a system for conditional gene inactivation in the mouse based on recombinase-mediated, unidirectional DNA inversion that can provide substantial coverage of the mouse genome. In this system, a gene trap vector is randomly integrated into mouse ES cells in a manner that allows identification of the integration site, reactivation of the allele by removal of the trap cassette and subsequent conditional inactivation of the trapped gene. The basis of the conditional gene inactivation is a genetic element that is transcriptionally silent when inserted within an intron; when inverted by site-specific recombination, the element disrupts endogenous mRNA production from the locus of integration. Here, we describe the design of the high throughput, conditional gene inactivation system, provide *in vitro* and *in vivo* evidence in support of inversion-based gene inactivation and report the results of an initial ES cell screen resulting in ES cell clones that are available to make mice suitable for conditional gene inactivation by crosses with specific Cre-expressing transgenic mice.

MATERIALS AND METHODS
=====================

Plasmid constructs
------------------

Oppositely oriented mutant loxP (mLoxP) ([@b7]) and equivalently oriented Flp recombinase recognition sites (FRT) ([@b8]) were synthesized and subcloned into pGEM-T (pGEM-loxP2 and pGEM-FRT2). The GT cassette (pGEM-GT) was assembled by subcloning PGK-TK, the PGK promoter upstream of the puromycin phosphotransferase gene, and conserved splice donor sequences into pGEM-FRT2 (EvoRV). The GI cassette (pGEM-GI) was made by inserting the human bcl-2 gene intron 2/exon 3 splice acceptor ([@b9]), the internal ribosome entry site of the encephalomyocarditis virus ([@b10]), an enhanced green fluorescent protein (eGFP) reporter gene and the bovine growth hormone polyadenylation signal sequence ([@b11]) (pA) into pGEM-mloxP2 (EcoRV). To construct the electroporation vector, the GT cassette flanked by FRT sites was released from pGEM-GT using NotI and XhoI and subcloned into the same sites in the pGEM-GI vector in the opposite orientation of the GT cassette (referred to pGEM-rGT-GI), then released by XhoI and SalI digestion and circularly ligated with a human immunoglobulin G coding region used to protect critical sequences from nuclease digestion ([@b12]).

The pCAGGS-GI/rGI-nlsDsRED constructs for transfecting mammalian cells were generated by replacing the Cre/polyA coding sequence in the pCAGGS-nlsCre vector ([@b13]) with a DsRED (Clontech)/pA fragment and inserting the GI cassette into the intron between the promoter and nlsDsRED in both orientations.

Genome walking and bioinformatics
---------------------------------

Selected ES cell clones were screened by Southern blotting for single or multiple insertions by probing EcoRI digested DNA with an eGFP fragment. The genome insertion site of clones with a single insertion was then determined by genome walking to obtain sequence on either side of the inserted cassette, using a modification of a method to amplify sequence between a single gene-specific primer and an unphosphorylated linker ([@b14]). Briefly, a double-stranded linker with an Tsp509I overhang was annealed from complementary single-strand oligonucleotides as shown below.

ES cell DNA was digested by Tsp509I, ligated to the unphosphorylated linker with T4 DNA ligase and column purified to remove excess linker. Oligonucleotide primers complimentary to the linker cassette and to either the 5′ or 3′ end of the gene trap (GT) cassette were used to amplify DNA between the cassette and the linker. The PCR products were diluted and amplified for the second time using a pair of nested primers complimentary to the trap cassette and linker (LCS1 and LCS2 above indicate the first and second round linker primers). The PCR products from the second round were sequenced directly after column purification. The tagged sequences were mapped to the mouse genome (NCBI Mouse build 32) by NCBI BLAST, using the Ensembl mouse 20.32b for gene annotation and a cutoff *E*-value for the BLAST analysis as 1 × 10^−10^ ([@b15],[@b16]). The top 10 blast targets and the DNA transcripts in the targeted region were manually evaluated using a visualization tool that we developed. Only insertions of correct orientation within an annotated gene or *ab initio* gene prediction are reported ([@b17]).

Cell transfection
-----------------

HEK293 cells were transfected with 0.8 μg of pCAGGS-revIC-nlsDsRED or pCAGGS-IC-nlsDsRED plasmid with and without 0.8 μg pCAGGSnls-cre plasmid DNA using 2 μl Lipofectamine 2000 (Invitrogen) for each well. Stable integrations were obtained by antibiotic selection and individual clones that had flipped to green were manually picked twice into 96 well plates for further expansion. Two of the eight colonies selected appeared 100% positive for eGFP and were transfected with Cre recombinase as described above and fluorescence recorded at 24 and 48 h after transfection. As a positive control, a stable HEK293 cell line carrying pCAGGS-IC-nlsDsRED was also transfected to insure Cre recombinase activity.

*In vitro* recombination assay
------------------------------

GI cassette plasmid DNA (2 μg, pGEM-GI) was incubated with Cre recombinase protein (80 U) in recombination buffer at 37°C. Aliquots were removed at time points indicated and placed in 5 μl of 5× cold stop buffer (0.2% SDS, 40 mM EDTA and 2 mg/ml proteinase K). DNA was extracted and digested by BamH1 and Xho1 at 37°C for 2 h. The DNA digestion pattern was examined by electrophoresis in a 0.8% agarose gel.

Transgenic mice
---------------

The pCAGGS-rGI transgene was prepared by replacing nlsCre in pCAGGS-nlsCre with the opposite orientation of the GI cassette. DNA was purified using a QIAEX II kit and injected into C57BL/6J × DBA/2J F~2~ zygotes by standard pronuclear microinjection techniques. Three founder lines were established on C57BL/6 backgrounds and crossed with Cre mice driven by the smMHC promoter ([@b18]) or an unpublished line developed by us that produces ubiquitous early embryonic Cre expression.

RESULTS
=======

Description of the conditional gene inactivation system: the double switch system
---------------------------------------------------------------------------------

The design of the gene trap/conditional gene inactivation vector is shown schematically in [Figure 1A](#fig1){ref-type="fig"}. The vector relies on two separate cassettes flanked by different site-specific DNA recombination recognition sequences, allowing for discrete control of each cassette. The GT cassette, consisting of a ubiquitous promoter (PGK), positive selection marker and splice donor sequence, is used to select for random integrations in mouse ES cells that have captured an endogenous gene polyadenylation signal ([@b4],[@b19]--[@b22]). The GT cassette, flanked by FRT, is removed from ES cell clones by transfection with Flp recombinase after confirmation of the integration site, restoring the allele to functionality ([Figure 1B](#fig1){ref-type="fig"}, first switch). To facilitate selection for ES cell clones in which the GT cassette has been removed, the cassette includes a negative selection element.

The gene inactivation (GI) cassette provides for conditional inactivation of genes in which intronic integration has occurred ([Figure 1B](#fig1){ref-type="fig"}). The basis of gene inactivation is a recombinase-mediated, unidirectional DNA inversion from transcriptionally silent to transcriptionally active mode. The GI cassette is in the opposite orientation of the GT cassette to prevent recognition of the strong splice acceptor (SA) \[human bcl-2 gene intron 2/exon 3 splice acceptor ([@b9])\] and polyadenylation (pA) signal sequences within the trapped locus; an IRES and eGFP reporter sequence serve to report the orientation of the GI cassette. These elements are flanked by mLoxP sites, which have previously been shown to promote irreversible deletion of a flanked sequence ([@b23],[@b24]). The mLoxP sequences are oriented in opposite directions to promote unidirectional inversion of the intervening sequence upon exposure to Cre recombinase ([@b25]). Thus, mice produced from ES cells containing the GI cassette in its anti-promoter orientation should have a functional allele, but when crossed with transgenic mice expressing Cre recombinase in a tissue-specific or temporally controlled manner, the transcriptionally silent GI cassette is irreversibly inverted and a fusion transcript of the truncated endogenous gene and the GI cassette formed by splicing, resulting in the expression of the reporter gene and premature termination of the endogenous gene mRNA ([Figure 1B](#fig1){ref-type="fig"}, second switch).

Transcriptional control by the recombinase-mediated unidirectional DNA inversion
--------------------------------------------------------------------------------

The effectiveness of a DNA inversion strategy to inactivate mouse genes in a conditional manner relies on several factors. The inserted GI cassette must not alter the expression of the trapped or targeted gene in its initial (inverted with respect to the endogenous promoter or anti-promoter) orientation, thereby insuring that the allele is functional in the absence of recombinase expression; once inverted by the recombinase (promoter orientation), the cassette must completely disrupt the expression of the endogenous gene so that full gene inactivation is achieved; and inversion of the DNA element *in vivo* must be efficient and unidirectional for the switch to be effective.

To determine the extent to which the GI cassette satisfies these conditions, we constructed reporter vectors incorporating the cassette in a manner that allowed determination of its transcriptional activity. The GI cassette, containing the flanking mLoxP sequences and the eGFP reporter, was placed in the first intron of the β-actin gene, downstream of the pCAGGS promoter ([@b13]), in either the anti-promoter or promoter orientation. The DsRED coding sequence with nuclear localization signal (nlsDsRED) was inserted downstream of the GI cassette in the second exon of the β-actin construct ([Figure 2A](#fig2){ref-type="fig"}). Optical separation of the fluorescence signals, as well as the nuclear localization of DsRED compared with the cytosolic expression of eGFP, allowed us to independently assess the orientation and transcriptional activity (silent or truncating) of the GI cassette, as well as the efficiency of recombinase-mediated inversion following transfection with Cre recombinase. HEK293 cells were transiently transfected with these constructs and examined at 24 and 72 h following transfection. As shown in [Figure 2B](#fig2){ref-type="fig"} (left panel), the expression of the GI cassette in its anti-promoter orientation resulted in the robust expression of the downstream reporter gene, DsRED. In two such experiments, the percentage of cells expressing DsRED was 24.5 and 30.8% 24 h after transfection, values roughly equivalent to the transfection efficiency of the experiment, indicating no detectable disruption of the downstream allele. However, when the GI cassette was inserted in the promoter orientation ([Figure 2B](#fig2){ref-type="fig"}, right panel), virtually all transcription of the downstream DsRED reporter gene was eliminated, whereas 32 and 48% were eGFP positive in two separate experiments. In these experiments, the percentage of eGFP positive cells was within the range of transfection efficiencies observed in our experiments (varied between 10 and 73% in all experiments), and the brightness of individual cells was equivalent to that observed with transient transfection of eGFP expression plasmids, indicating that the GI cassette pseudo exon was incorporated into RNA by the transcriptional machinery in a highly efficient manner and produced a robust transcriptional block. Experiments in which a Cre recombinase expression plasmid was co-transfected with the inverted GI constructs resulted in the expected manipulation of the GI cassette; 90% of transfected cells (expressing either fluorophore) were eGFP positive. Similarly, 79% of cells co-transfected with Cre and the GI cassette in the promoter orientation (green) flipped to red ([Figure 2](#fig2){ref-type="fig"}). Because the transient transfection of the constructs and the stability of the translated proteins precluded a clear assessment of the efficiency of DNA inversion, we constructed stable cell lines with the same constructs. In four such experiments, 27.6% of cells were flipped from one orientation to the other (range of 15--44%), a figure close to the transfection efficiency for these experiments.

We next investigated the efficiency of mLoxP sequences ([@b23]), which have previously been shown to promote irreversible gene deletion ([@b24]), in catalyzing the required unidirectional DNA inversion. LoxP recognition sequences placed in opposite orientations lead to Cre recombinase catalyzed inversion of the intervening sequence, such that at equilibrium 50% of the intervening sequence is in each orientation ([@b23],[@b26]). As shown in [Figure 3](#fig3){ref-type="fig"}, restriction digest analysis of plasmid DNA containing the GI cassette flanked by oppositely oriented mLoxP sites indicated that Cre recombinase protein resulted in a rapid and unidirectional inversion of the cassette *in vitro*, resulting in a predictable alteration in DNA fragment sizes. Greater than 90% of the DNA was inverted within 1 h of exposure to 80 U Cre recombinase at 37°C, indicating efficient recognition of the mutant sequence by Cre recombinase, and a markedly reduced binding affinity for the recombined sequence.

The unidirectional nature of this inversion was further confirmed in cells containing stable insertions of the GI cassette. In these experiments, the reporter construct described above, containing an antibiotic resistance cassette, was transfected in its anti-promoter (red) orientation and stable integrants were selected with G418. Surviving cells displayed no eGFP fluorescence and were virtually all positive for DsRED. These cells were transfected with Cre recombinase and eGFP positive clones manually picked twice to obtain homogenous eGFP-expressing cultures, in which the GI cassette had been flipped into the same orientation as the upstream promoter. As shown in [Figure 4](#fig4){ref-type="fig"}, subsequent transfections of these cells with Cre recombinase failed to produce any DsRED-positive cells, indicating that once inverted, the GI cassette could no longer flip to the anti-promoter orientation, whereas transfection of control cells stably expressing the cassette in the promoter (green) orientation with Cre recombinase resulted in the marked expression of DsRED. These results indicate that once inverted, the GI cassette is insensitive to the recombinase.

Transfection of cell lines may result in a far greater expression of Cre recombinase than can be achieved *in vivo* in the mouse. To confirm the effectiveness of DNA inversion in a more practical context, we created lines of transgenic mice, in which the transgene consisted of the GI cassette, flanked by mLoxP sites ([Figure 5A](#fig5){ref-type="fig"}), was inserted in the pCAGGS plasmid ([@b13]) in the opposite orientation of the CMV promoter/β-actin enhancer. Hemizygous GI^+^ mice were crossed with mice expressing Cre recombinase under control of the smooth muscle-specific myosin heavy chain promoter ([@b18]), or with mice that direct Cre expression to all tissues of the early embryo (K.-Y. Deng, H.-B. Xin and M.I. Kotlikoff., manuscript in preparation), and tissues analyzed for fluorescence and construct orientation to determine the extent to which the cassette is inverted *in vivo*. As shown in [Figure 5B](#fig5){ref-type="fig"}, PCR analysis of the tissues of offspring from these crosses using primers specific for the promoter orientation of the GI cassette indicated that only double transgenic (Cre^+^/GI^+^) mice contained the flipped cassette, and that this orientation of the cassette was specific to tissues in which Cre recombinase expression was directed. In litters from two separate founders, three-week-old double transgenic (GI^+^/smCre^+^) mice displayed robust eGFP fluorescence confined to vascular and nonvascular smooth muscle tissues ([Figure 5C](#fig5){ref-type="fig"}), consistent with the cellular expression of Cre recombinase. Mice carrying the GI cassette but not the Cre transgene never displayed eGFP fluorescence. Moreover, analysis of offspring from crosses producing early embryonic expression of Cre recombinase resulted in a generalized inversion of the GI cassette, as indicated by robust fluorescence of all cells in 8 and 18.5 day mice ([Figure 5D](#fig5){ref-type="fig"}).

Gene trapping and determination of insertion site
-------------------------------------------------

Unlike insertional mutagenesis in which 3′ RACE can be used to identify a disrupted exon sequence, conditional gene inactivation by DNA inversion and transcriptional block requires intronic insertion, and unambiguous determination of the site of vector integration is therefore necessitated. To test the described vectors and establish the feasibility of identification strategies, a gene trap screen was conducted in R1 ES cells by electroporating cells in the presence of gene trap vector DNA ([Figure 1A](#fig1){ref-type="fig"}). Cells were selected with puromycin for productive integrations and resistant clones transferred to triplicate 96 well plates, one of which was used to make DNA for sequencing. Resistant colonies were first screened by Southern blotting with an eGFP fragment after digestion with EcoR1. Of 239 resistant clones, a single band was identified in 136 clones, with multiple bands in 64 clones and no evidence of insertion in the remaining clones.

Several sequencing strategies were pursued to obtain genomic sequence flanking the integrated vector. The most successful method was a modification of a genome walking procedure ([@b14]), which allowed unambiguous determination of the exact site of vector integration in a high percentage of cases. Amplification of flanking DNA by genome walking resulted in useable sequence from one end or both ends of the cassette in 81 (60%) of the single integrants. As shown in [Table 1](#tbl1){ref-type="table"}, our bioinformatics strategy resulted in the identification of the locus of insertion in 39 clones, or 48% of the clones in which flanking sequence was obtained. This is a conservative estimate, as only known or *ab initio* predicted genes were considered in the analysis, whereas in many cases, expressed sequence tag (EST) data or separate analysis of the local sequence by Genscan suggested the presence of a potential gene locus, within which the vector was appropriately oriented to capture the polyadenylation sequence. In addition, although flanking sequences allowed determination of the site of integration in over 90% of the clones examined, in many cases the trapped polyadenylation sequence could not be unambiguously determined and was therefore not listed. These failures could be attributed to incomplete annotation or inadequate sequence (a substantial number of insertions in which the gene locus could not be identified occurred in areas of the genome that contain substantial sequence gaps), but could also result from the trapping of pseudo polyadenylation sequences that are not associated with an endogenous gene. Of the unambiguous integrants shown in [Table 1](#tbl1){ref-type="table"}, 56% were intronic, whereas 28% occurred in the 5′-untranslated region (5′-UTR), an average of 114 bp from the start of exon 1. Thus, in this screen ∼10% of all resistant clones could be identified as intronic insertions in known genes.

DISCUSSION
==========

Our experiments demonstrate the practical basis of the unidirectional DNA inversion for the production of conditional knockout mice. We have shown that (i) the inserted DNA vector is transcriptionally silent before activation; (ii) following unidirectional inversion the vector powerfully disrupts transcription; (iii) unidirectional inversion of the cassette can be efficiently achieved in cells and in transgenic mice; (iv) gene trapping results in numerous single intronic insertions within endogenous genes; (v) the GT cassette can be readily removed leaving the transcriptionally silent inverted element; and (vi) the site of insertion is easily determined. Taken together, these experiments indicate that unidirectional DNA inversion is an effective strategy for control of gene expression *in vivo*. The combination of unidirectional gene inversion with gene trap methods provides a high-throughput method for the generation of knockout mice.

We used a gene trap vector designed for electroporation to conduct a small-scale screen for ES cells with single, intronic insertions. The overall throughput for unambiguous insertions of this nature was 10%, which when scaled should yield many hundreds of useful clones. Throughput would likely be markedly enhanced by incorporation of the cassettes within a retroviral vector, providing for more efficient transfer of the vector and increasing the percentage of single insertions ([@b27]). Additionally, replacement of the GT cassette ([Figure 1A](#fig1){ref-type="fig"}) with an FRT-flanked selection cassette oriented inverse to the inactivation cassette, and flanking both cassettes with homologous sequences, enables the system\'s use as a targeted replacement vector. In this application, the vector would be targeted to an intron, which simplifies vector construction as minor PCR errors and frame shifts are not a concern; alternatively, the vector could be targeted to an intronic locus in a mouse bacterial artificial chromosome to produce highly efficient targeting vectors ([@b28]--[@b31]). These application would extend the utility of inversion-based gene inactivation, as gene trap approaches are limited by several factors including poor accessibility of some genes, a relatively high percentage of trapped sequences that are not expressed as mRNA and recombinations at the site of insertion ([@b32],[@b33]).

A key requirement in the implementation of a gene trapping/conditional knockout strategy is the determination of the location of insertion of the vector, insuring that insertion is intronic and allowing a determination of the likely functional result of transcriptional termination at the insertion site. In cases of gene overlap, knowledge of the insertion site is particularly important. The genome walking method described here allows rapid and efficient determination of flanking sequence, and the attendant employment of bioinformatics strategies to rapidly determine the location of the insertion and the identity of the gene locus from sequence databases. Determination of the insertion site was achieved in 60% of the single insertion clones, and repeated analysis of the other clones would probably improve this percentage. A significant limitation in the use of the sequence information was ambiguity as to the trapped gene locus; as mammalian gene annotation continues, we anticipate attendant improvements in the determination of functionally relevant insertions.

One limitation of the described transcriptional arrest strategy should be noted: the assumption of conservation of function of a trapped allele following removal of the GT cassette assumes minimal transcriptional effects associated with the intronic insertion of the GI cassette. As *cis* transcriptional effects associated with intronic insertions are well documented and can result in inefficient or aberrant RNA splicing ([@b34],[@b35]), a careful evaluation of the transcriptional function of the trapped allele seems prudent. We have not evaluated this effect as its importance will depend on the nature of the insertion (which intron and where within the intron), as well as the extent of alternative splicing of the specific gene. We also note that the described ES cell collection can also be used to create mice with a constitutively inactivated allele by inverting the GI cassette *in vitro* and retaining the GT cassette.

While still emerging, conditional gene expression strategies in the mouse have already had major impacts on cancer biology and immunobiology. It is likely that temporal and tissue-specific control of the expression of virtually all clinically relevant genes will be achieved in the mouse over the next two decades. The above described system should provide important advantages in the achievement of this goal, and should also be useful for the functional annotation of genes of other eukaryotic species.
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![Vectors and conditional gene inactivation system. (**A**) Schematic representation of the gene trap vector. GI, gene inactivation; GT, gene trap cassettes; SA, splice acceptor; pA, polyadenylation signal; Neg, negative selection cassette; mLoxP, mutant LoxP sequence; LE, RE, left and right LoxP elements; PS, protection sequence to protect vector from exonuclease digestion; FRT, Flp recombinase recognition site; PGK-Puro-SD, phosphoglycerate kinase promoter directing expression of the puromycin phosphotransferase gene followed by a splice donor sequence; and PGK-TK-pA, the same promoter driving the thymidine kinase coding sequence for negative selection. (**B**) Schematic representation of double switch system. The GI cassette is transcriptionally inactive until inverted *in vivo*.](gni016f1){#fig1}

![Orientation-dependent transcriptional activity of the gene inactivation cassette. (**A**) Schematic representation of reporter vectors. The nlsDsRED sequence was inserted into the second exon of the β-actin gene (arrow denotes remaining partial second exon) and the GI cassette (containing IRES-eGFP) inserted in anti-promoter (rev) and promoter orientations. (**B**) Vectors were transfected into HEK293 cells. In the anti-promoter orientation, no eGFP activity was observed and the construct had no effect on dsRED expression (top left), whereas in the promoter orientation, the GI cassette ablated expression DsRED (top right) and the expression of eGFP was equivalent to control plasmid transfections. Subsequent transfection of these cultures with Cre recombinase resulted in conversion to the opposite transcriptional state at 24 h. Note transient transfection and protein lifetime prevents evaluation of extent of conversion.](gni016f2){#fig2}

![Unidirectional DNA inversion by mLoxP sequences *in vitro*. (**A**) Plasmid components with Xho1 and BamH1 sites. The insert and plasmid backbone are 2.6 and 3.0 kb, respectively. Digestion of the vector in the constructed orientation results in 2.0 and 3.6 kb (3.0 plasmid + 0.6 insert) products. Inversion of the insert reduces the size of the insert fragment to 0.6 kb, resulting in a 5 kb product. (**B**) Plasmid at top was exposed to Cre recombinase protein for the times shown, digested with BamH1 and Xho1 and separated on agarose gel (above). The 2.0 and 3.6 kb bands are eliminated with increasing time of exposure to the enzyme and the predicted 5 kb band is seen (0.6 kb band not shown). The graph (below) shows densitometric quantification of the original 3.6 kb band.](gni016f3){#fig3}

![Unidirectional DNA inversion *in vivo*. Left, cells were selected for stable expression of the GI cassette in its transcriptionally silent (anti-promoter, red) orientation, transfected with Cre recombinase expression plasmid to invert the cassette, and green clones selected. Top and middle are eGFP and DsRED images of same fields. Following an additional transfection with Cre recombinase, no inversion of the previously flipped cassette occurred (bottom, DsRED image). Right, control cells stably transfected with the GI cassette in its transcriptionally active (promoter, green) orientation demonstrated robust gene inversion when transiently transfected with Cre recombinase. Bottom images taken 48 h post-Cre transfection.](gni016f4){#fig4}

![Recombinase-mediated DNA inversion in transgenic mice. (**A**) Transgene containing the GI cassette (with eGFP reporter) driven by the pCAGGS. (**B**) Genotyping of F1 offspring of GI^+^ and Cre recombinase transgenic mice expressed in smooth muscle (lanes 1--3) or whole embryo (lane 4). Only mice in lanes 3 and 4 expressed both the GI and Cre recombinase transgenes. Using primers specific for the inverted form of the cassette, a PCR product was detected in DNA prepared from smooth muscle tissue (lane 3) or whole embryo (lane 4) only in mice expressing both transgenes. (**C**) Tissue from double transgenic mice with smooth muscle restricted Cre expression. Left, light (above) and fluorescent (below) images of urinary bladders from Cre^−^,GI^+^ (left) and Cre^+^,GI^+^ mice (middle and right); 0.8×. Right, superimposed light and fluorescent image of artery from Cre^−^,GI^+^ mouse shows fluorescence restricted to smooth muscle; 10×. (**D**) Left, light (above) and fluorescent (below) images of tails from 18.5 day mice. Tails at left and right: Cre^+^,GI^+^; tails in middle: Cre^−^,GI^+^. Fluorescence is muted by pigment in tail at left. Right, fluorescent image of 8 day Cre^+^,GI^+^ mouse upper body tissues.](gni016f5){#fig5}

###### 

List of trapped genes and insertion sites

  Gene trap clones                                                                   
  ------------------ -------------- ----------------- ------------------------------ ----------------------------------------------------------------------------------------
  AB4                11:46999933    Intron 2 (4)      GENSCAN00000030349             Unknown
  AB6                3:20959528     5′ UTR (1.2 kb)   Genscan prediction             Unknown
  AB7                19:4600746     5′ UTR (147 bp)   ENSMUSG00000006456             Rbm14 Unknown function, RNA-binding region RNP-1 (RNA recognition motif)
  AB10               19:9205621     5′ UTR (73)       ENSMUSG00000044504             Zbtb3, zinc finger and BTB domain containing 3
  AB23               Y:3064117      Intron 3 (9)      ENSMUSG00000053211             Zfy1, zinc finger protein 1, Y linked
  AB24               1:24787681     Intron 1 (16)     ENSMUSG00000026139             LMBR membrane protein (lipocalin like motif)
  AB34               5:129049765    3′ UTR (1.2 kb)   ENSMUSESTG00000024736          Unknown
  AB35               8:97091210     5′ UTR (48 bp)    ENSMUSESTG00000002583          Unknown
  AB41               11:14526302    Intron 2 (3)      GENSCAN00000063363             Nuclear envelope pore membrane protein POM 121
  AB45               3:33612037     5′ UTR (5)        ENSMUSG00000027671             53 kDa BRG1-associated factor A (actin-related protein BAF53A)
  AB52               15:83418824    5′ UTR (108 bp)   ENSMUSG00000022478             Phf5a (PHD finger protein 5a)
  AB57               13:97799446    Exon 1(1)         GENSCAN00000141083             Unknown
  AB60               7:37794879     5′ UTR (119 bp)   ENSMUSG00000025389             Lens fiber major intrinsic protein (mip26)
  AB61               9:46147000     5′ UTR (307)      ENSMUSG00000032115             Hyou1 Cab140) hypoxia up-regulated 1
  AB72               18:84776833    Intron 1(5)       GENSCAN00000002917             Unknown
  AB82               15:77123042    Intron 4(7)       ENSMUSG00000053168             Ly6c lymphocytes antigen LY-6C precursor
  AB112              15:91187795    5′ UTR (72 bp)    ENSMUSG00000022618             Chk1, choline/ethanolamine kinase
  AB122              14:110179384   Intron 1(2)       [ENSMUSESTG00000021020]{.ul}   Unknown
  AB162              9:63143799     Intron 3(5)       GENSCAN00000046398             Unknown
  AB166              1:108891482    Exon 2(2)         ENSMUSG00000048549             Bcl2. apoptosis regulator
  AB167              6:104002195    Intron 2(21)      ENSMUSG00000030075             Cntn3, contactin 3; plasmacytoma-associated neuronal glycoprotein
  AB172              7:NT_081205    Exon 1(9)         GENSCAN00000100015             Unknown
  AB179              15:77109835    Intron 3(5)       ENSMUSG00000053168             Ly6c, similar to lymphocyte antigen 6 complex, locus I
  AB191              X:81394369     Intron 2(3)       GENSCAN00000021466             Unknown
  AB203              8:95320457     5′ UTR (191 bp)   [ENSMUSG00000033009]{.ul}      Prolyl 4-hydroxylase, alpha subunit
  AB208              3:30902840     Intron 1(15)      ENSMUSG00000027684             Evi1, ecotropic viral integration site 1 (embryonic lethal)
  AA3                7:66130092     5′ UTR (74)       ENSMUSESTT00000000727          Unknown
  AA4                9:125575183    Intron 1(5)       ENSMUSG00000035498             Unknown
  B6                 15:9404595     Intron 4(6)       ENSMUSG00000055463             Unknown
  B2                 19:35685964    Intron 1(3)       GENSCAN00000029475             Unknown
  AC2                X:125314423    Intron 1(3)       ENSMUSESTT00000005143          Morf4l2, transcription factor-like protein MORF-related gene X protein. Splice variant
  AE1                4:117345976    Intron 11(21)     GENSCAN00000056387             Cdc20, cell division cycle protein 20 homolog. Splice variant
  AD2                14:16382207    Intron 2(3)       GENSCAN00000011182             Unknown
  AD8                1:134403527    Intron 1(2)       GENSCAN00000079343             Unknown
  AE2                11:118712586   Intron 3(12)      ENSMUSG00000039976             Unknown, RabGAP/TBC domain
  AF2                11:70076743    Exon 1 (5)        ENSMUSG00000018919             Tm4sf5, transmembrane 4 superfamily, member 5, unknown function
  AG2                1:63421977     Intron 1(3)       ENSMUSESTG00000010455          Unknown
  AG9                2:32724693     Exon 1(2)         ENSMUSG00000039164             Unknown
  AH2                17:8732662     Intron 1(2)       GENSCAN00000120409             Unknown
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